Recombinant Human Papillomavirus Bivalent Vaccine — Competitive Intelligence Brief

Recombinant Human Papillomavirus Bivalent Vaccine (Recombinant Human Papillomavirus Bivalent Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prophylactic vaccine. Area: Oncology / Immunology.

marketed Prophylactic vaccine Human papillomavirus types 16 and 18 (HPV-16, HPV-18) Oncology / Immunology Biologic

Target snapshot

Recombinant Human Papillomavirus Bivalent Vaccine (Recombinant Human Papillomavirus Bivalent Vaccine) — National Cancer Institute (NCI). This vaccine stimulates the immune system to produce antibodies against two types of human papillomavirus (HPV-16 and HPV-18) to prevent infection and cervical cancer development.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Recombinant Human Papillomavirus Bivalent Vaccine TARGET	Recombinant Human Papillomavirus Bivalent Vaccine	National Cancer Institute (NCI)	marketed	Prophylactic vaccine	Human papillomavirus types 16 and 18 (HPV-16, HPV-18)
HPV vaccine	HPV vaccine	Fondazione IRCCS Policlinico San Matteo di Pavia	marketed	Prophylactic vaccine	Human papillomavirus (HPV) capsid proteins / L1 antigen
Flu Vaccine	Flu Vaccine	La Fundacion Favaloro para la Investigacion y la Docencia Medica	marketed	Prophylactic vaccine	Influenza A and B viral hemagglutinin and neuraminidase surface antigens
Human Papillomavirus	Human Papillomavirus	Peking Union Medical College Hospital	marketed	Prophylactic vaccine	Human Papillomavirus capsid protein (L1)
Cervarix TM	Cervarix TM	GlaxoSmithKline	phase 3	Prophylactic vaccine	HPV types 16 and 18 (L1 capsid protein)
HPV-16/18 L1 VLP AS04	HPV-16/18 L1 VLP AS04	GlaxoSmithKline	phase 3	Prophylactic vaccine	HPV-16 and HPV-18 L1 capsid protein
GSK580299 (Cervarix)	GSK580299 (Cervarix)	GlaxoSmithKline	phase 3	Prophylactic vaccine	HPV type 16 and 18 L1 capsid protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prophylactic vaccine class)

1. GlaxoSmithKline · 5 drugs in this class
2. La Fundacion Favaloro para la Investigacion y la Docencia Medica · 1 drug in this class
3. Fondazione IRCCS Policlinico San Matteo di Pavia · 1 drug in this class
4. National Cancer Institute (NCI) · 1 drug in this class
5. Peking Union Medical College Hospital · 1 drug in this class
6. Shanghai Zerun Biotechnology Co.,Ltd · 1 drug in this class
7. Murdoch Childrens Research Institute · 1 drug in this class